BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31018952)

  • 1. Pathogenic and Targetable Genetic Alterations in Resected Recurrent Undifferentiated Pleomorphic Sarcomas Identified by Targeted Next-generation Sequencing.
    Zheng B; Qu Y; Wang J; Shi Y; Yan W
    Cancer Genomics Proteomics; 2019; 16(3):221-228. PubMed ID: 31018952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma.
    Lewin J; Garg S; Lau BY; Dickson BC; Traub F; Gokgoz N; Griffin AM; Ferguson PC; Andrulis IL; Sim HW; Kamel-Reid S; Stockley TL; Siu LL; Wunder JS; Razak ARA
    Int J Cancer; 2018 Jan; 142(1):57-65. PubMed ID: 28891048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profiling of potential driver mutations in sarcomas by targeted next generation sequencing.
    Andersson C; Fagman H; Hansson M; Enlund F
    Cancer Genet; 2016 Apr; 209(4):154-60. PubMed ID: 26987750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular profiling of soft tissue sarcomas using next-generation sequencing: a pilot study toward precision therapeutics.
    Jour G; Scarborough JD; Jones RL; Loggers E; Pollack SM; Pritchard CC; Hoch BL
    Hum Pathol; 2014 Aug; 45(8):1563-71. PubMed ID: 24908143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted next-generation sequencing of CIC-DUX4 soft tissue sarcomas demonstrates low mutational burden and recurrent chromosome 1p loss.
    Lazo de la Vega L; Hovelson DH; Cani AK; Liu CJ; McHugh JB; Lucas DR; Thomas DG; Patel RM; Tomlins SA
    Hum Pathol; 2016 Dec; 58():161-170. PubMed ID: 27664537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next-Generation Sequencing for Patients with Sarcoma: A Single Center Experience.
    Cote GM; He J; Choy E
    Oncologist; 2018 Feb; 23(2):234-242. PubMed ID: 28860410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Novel Fusion Transcripts in Undifferentiated Pleomorphic Sarcomas by Transcriptome Sequencing.
    Zheng B; Zhang S; Cai W; Wang J; Wang T; Tang N; Shi Y; Luo X; Yan W
    Cancer Genomics Proteomics; 2019; 16(5):399-408. PubMed ID: 31467233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A genomic survey of sarcomas on sun-exposed skin reveals distinctive candidate drivers and potentially targetable mutations.
    Miller TI; Zoumberos NA; Johnson B; Rhodes DR; Tomlins SA; Chan MP; Andea AA; Lucas DR; McHugh JB; Smith N; Harms KL; Brewer C; Saleh J; Patel RM; Harms PW
    Hum Pathol; 2020 Aug; 102():60-69. PubMed ID: 32540221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pan-cancer Genomic Analysis of AXL Mutations Reveals a Novel, Recurrent, Functionally Activating AXL W451C Alteration Specific to Myxofibrosarcoma.
    Williams EA; Vegas I; El-Senduny FF; Zhang J; Mata DA; Hiemenz MC; Hughes SR; Sa BC; Kraft GP; Gorbatov N; Foley-Peres K; Sanchez EZ; Milikowski C; Williams KJ; Ross JS; Kurzrock R; Montgomery EA; Lombard DB; Kumar S
    Am J Surg Pathol; 2024 Jun; 48(6):699-707. PubMed ID: 38369783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas.
    Serrano C; Romagosa C; Hernández-Losa J; Simonetti S; Valverde C; Moliné T; Somoza R; Pérez M; Vélez R; Vergés R; Domínguez R; Carles J; Ramón Y Cajal S
    Cancer; 2016 Jan; 122(1):99-107. PubMed ID: 26479291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of bone.
    Ali NM; Niada S; Brini AT; Morris MR; Kurusamy S; Alholle A; Huen D; Antonescu CR; Tirode F; Sumathi V; Latif F
    J Pathol; 2019 Feb; 247(2):166-176. PubMed ID: 30281149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic profiling of pleomorphic rhabdomyosarcoma reveals a genomic signature distinct from that of embryonal rhabdomyosarcoma.
    Saoud C; Dermawan JK; Sharma AE; Tap W; Wexler LH; Antonescu CR
    Genes Chromosomes Cancer; 2024 May; 63(5):e23238. PubMed ID: 38722224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer.
    Lo Iacono M; Buttigliero C; Monica V; Bollito E; Garrou D; Cappia S; Rapa I; Vignani F; Bertaglia V; Fiori C; Papotti M; Volante M; Scagliotti GV; Porpiglia F; Tucci M
    Oncotarget; 2016 Mar; 7(12):14394-404. PubMed ID: 26887047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A primary undifferentiated pleomorphic sarcoma of the lumbosacral region harboring a LMNA-NTRK1 gene fusion with durable clinical response to crizotinib: a case report.
    Zhou N; Schäfer R; Li T; Fang M; Liu L
    BMC Cancer; 2018 Aug; 18(1):842. PubMed ID: 30134855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation on the Genomic Characterization of Uterine Sarcoma for rAd-
    Xia Y; Wang L; Ma X; Li X
    Hum Gene Ther; 2020 Aug; 31(15-16):881-890. PubMed ID: 32013587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system.
    van de Nes J; Gessi M; Sucker A; Möller I; Stiller M; Horn S; Scholz SL; Pischler C; Stadtler N; Schilling B; Zimmer L; Hillen U; Scolyer RA; Buckland ME; Lauriola L; Pietsch T; Waha A; Schadendorf D; Murali R; Griewank KG
    J Neurooncol; 2016 May; 127(3):435-44. PubMed ID: 26744134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Undifferentiated pleomorphic sarcoma with co-existence of KRAS/PIK3CA mutations.
    Li B; Li L; Li X; Wang Y; Xie Y; Liu C; Li F
    Int J Clin Exp Pathol; 2015; 8(7):8563-7. PubMed ID: 26339434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Undifferentiated and Dedifferentiated Metastatic Melanomas Masquerading as Soft Tissue Sarcomas: Mutational Signature Analysis and Immunotherapy Response.
    Kasago IS; Chatila WK; Lezcano CM; Febres-Aldana CA; Schultz N; Vanderbilt C; Dogan S; Bartlett EK; D'Angelo SP; Tap WD; Singer S; Ladanyi M; Shoushtari AN; Busam KJ; Hameed M
    Mod Pathol; 2023 Aug; 36(8):100165. PubMed ID: 36990277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targetable Alterations in Adult Patients With Soft-Tissue Sarcomas: Insights for Personalized Therapy.
    Lucchesi C; Khalifa E; Laizet Y; Soubeyran I; Mathoulin-Pelissier S; Chomienne C; Italiano A
    JAMA Oncol; 2018 Oct; 4(10):1398-1404. PubMed ID: 29801054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.